PAMIDRONATE DISODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pamidronate Disodium, and what generic alternatives are available?
Pamidronate Disodium is a drug marketed by Aesgen, Am Regent, Areva Pharms, Dr Reddys, Fresenius Kabi Usa, Hikma, Hospira, Mn Pharms, Mylan Labs Ltd, Sagent Pharms Inc, Sun Pharma Global, and Teva Pharms Usa. and is included in fourteen NDAs.
The generic ingredient in PAMIDRONATE DISODIUM is pamidronate disodium. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pamidronate disodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pamidronate Disodium
A generic version of PAMIDRONATE DISODIUM was approved as pamidronate disodium by HIKMA on April 30th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PAMIDRONATE DISODIUM?
- What are the global sales for PAMIDRONATE DISODIUM?
- What is Average Wholesale Price for PAMIDRONATE DISODIUM?
Summary for PAMIDRONATE DISODIUM
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 159 |
Clinical Trials: | 8 |
Patent Applications: | 3,729 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PAMIDRONATE DISODIUM at DailyMed |
![PAMIDRONATE DISODIUM drug patent expirations Drug patent expirations by year for PAMIDRONATE DISODIUM](/p/graph/s/t/PAMIDRONATE_DISODIUM-patent-expirations.png)
Recent Clinical Trials for PAMIDRONATE DISODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Peking Union Medical College Hospital | Phase 1 |
The Hospital for Sick Children | N/A |
National Cancer Institute (NCI) | Phase 1 |
Pharmacology for PAMIDRONATE DISODIUM
Drug Class | Bisphosphonate |